Endocrine therapy for postmenopausal women with hormone receptor-positive her2-negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: A canadian consensus statement

Current Oncology

Volumn 20, Issue 1, 2013, Pages 48-61

  Pritchard, Kathleen I ^a   Gelmon, K A ^b   Rayson, D ^c   Provencher, L ^d   Webster, M ^e   McLeod, D ^f   Verma, S ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e TOM BAKER CANCER CENTRE   (Canada)

^f Kaleidoscope Strategic   (Canada)

Author keywords

Advanced breast cancer; Endocrine resistance; Endocrine therapy; Everolimus; Exemestane; Fulvestrant; Mtorinhibitor; Nonsteroidal aromatase inhibitor

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; EXEMESTANE; FULVESTRANT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; TAMOXIFEN;

ADVANCED CANCER; ARTHRALGIA; ARTHROPATHY; ARTICLE; ASTHENIA; BREAST BIOPSY; BREAST CANCER; CANADA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONSENSUS DEVELOPMENT; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; INFECTION; LETHARGY; LOADING DRUG DOSE; METASTASIS; NAUSEA; OVERALL SURVIVAL; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; RISK FACTOR; STOMATITIS; VOMITING;

EID: 84873444298     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1316     Document Type: Article

References (53)

1. Canadian Cancer Society. Breast Cancer Statistics at a Glance [Web page]. Toronto, ON: Canadian Cancer Society; 2012. [Available at: http://www.cancer.ca/Canada-wide/About%20 cancer/Cancer%20statistics/Stats%20at%20a%20glance/ Breast%20cancer.aspx?sc_lang=EN; cited September 27, 2012]
2. Kennecke HF, Ellard S, O'Reilly S, Gelmon KA. New guidelines for treatment of early hormone-positive breast cancer with tamoxifen and aromatase inhibitors. BC Med J 2006;48:121-6.
3. Villarreal-Garza C, Cortes J, Andre F, Verma S. mtor inhibitors in the management of hormone receptor-positive breast cancer: the latest evidence and future directions. Ann Oncol 2012;23:2526-35.
4. Huang HJ, Neven P, Drijkoningen M, et al. Association between tumour characteristics and her-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005;58:611-16.
5. National Comprehensive Cancer Network (nccn). Breast Cancer. NCCN Clinical Practice Guidelines in Oncology. Ver. 3.2012. Fort Washington, PA: nccn; 2012. [Available online at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (free registration required); cited September 16, 2012]
6. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (abc 1). Breast 2012;21:242-52.
7. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
8. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase iii study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596-606.
9. Paridaens RJ, Dirix LY, Beex LV, et al. Phase iii study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883-90.
10. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase ii trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a gineco study. J Clin Oncol 2012;30:2718-24.
11. Bedard PL, Freedman OC, Howell A, Clemons M. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? Breast Cancer Res Treat 2008;108:307-17.
12. Bachelot T, Bourgier C, Cropet C, et al. tamrad: a gineco randomized phase ii trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, her2 negative metastatic breast cancer (mbc) with prior exposure to aromatase inhibitors (ai) [abstract S1-6]. Presented at the 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. [Available online at: http://www.abstracts2view.com/sabcs10/view.php?nu=SABCS10L_230&terms=; cited September 28, 2012]
13. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase iii tandem study. J Clin Oncol 2009;27:5529-37.
14. Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for her-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010;15:122-9.
15. Cristofanilli M, Valero V, Mangalik A, et al. Phase ii, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010;16:1904-14.
16. Osborne CK, Neven P, Dirix LY, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase ii study. Clin Cancer Res 2011;17:1147-59.
17. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ici 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403.
18. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981;304:16-21.
19. Allegra JC, Bertino J, Bonomi P, et al. Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol 1985;12:61-4.
20. Gill PG, Gebski V, Snyder R, et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 1993;4:741-4.
21. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982;5:155-60.
22. Morgan LR. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients. Semin Oncol 1985;12:43-7.
23. Muss HB, Wells HB, Paschold EH, et al. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis-a phase iii trial of the Piedmont Oncology Association. J Clin Oncol 1988;6:1098-106.
24. Paterson AH, Hanson J, Pritchard KI, et al. Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer. Semin Oncol 1990;17:52-62.
25. Miller WR, Bartlett J, Brodie AM, et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008;13:829-37.
26. Lonning PE. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 2009;45:527-35.
27. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73.
28. DeFriend DJ, Howell A, Nicholson RI, et al. Investigation of a new pure antiestrogen (ici 182780) in women with primary breast cancer. Cancer Res 1994;54:408-14.
29. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001;61:6739-46.
30. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13.
31. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptorpositive, advanced breast cancer: results from efect. J Clin Oncol 2008;26:1664-70.
32. Johnston S, Kilburn LS, Ellis P, et al. Fulvestrant alone or with concomitant anastrozole vs. exemestane following progression on non-steroidal aromatase inhibitor-first results of the sofea trial (cruke/03/021 and cruk/09/007) (isrctn44195747) [abstract LBA2]. Eur J Cancer 2012;48(suppl3):S2.
33. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the confirm phase iii trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600.
34. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010;16:1979-87.
35. Burstein HJ. Novel agents and future directions for refractory breast cancer. Semin Oncol 2011;38(suppl 2):S17-24.
36. Johnston SR. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer. Clin Cancer Res 2006;12:1061s-8s.
37. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331S-6S.
38. Baselga J, Roche H, Fumoleau P. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study [abstract 1068]. Breast Cancer Res Treat 2005;94(suppl 1):S62.
39. Bhattacharyya GS, Biswas J, Singh JK, et al. Reversal of tamoxifen resistance (hormone resistance) by addition of sirolimus (mtor inhibitor) in metastatic breast cancer [abstract 16LBA]. Eur J Cancer 2011;47(suppl 2):9.
40. Chow L, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer [abstract 6091]. Breast Cancer Res Treat 2006;100(suppl 1):S286.
41. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
42. Hortobagyi GN, Piccart M, Rugo H, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the bolero-2 phase iii trial [abstract S3-7]. Presented at the 34th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 6-9, 2011. [Available online at: http://www.abstracts2view.com/sabcs11/view.php?nu=SABCS11L_1653; cited November 15, 2012]
43. Kaniklidis C. Fulvestrant loading, tumor markers, and ongoing trials. Comm Oncol 2007;4:649-50.
44. Young OE, Renshaw L, Macaskill EJ, et al. Effects of fulvestrant 750 mg in premenopausal women with oestrogenreceptor-positive primary breast cancer. Eur J Cancer 2008;44:391-9.
45. Piccart M, Noguchi S, Pritchard K, et al. Everolimus for postmenopausal women with advanced breast cancer: updated results of the bolero-2 phase iii trial [abstract 559]. J Clin Oncol 2012;30:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101092; cited November 1, 2012]
46. Verma S, McLeod D, Batist G, Robidoux A, Martins IR, Mackey JR. In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 2011;16:25-35.
47. Gnant M, Baselga J, Rugo HS, et al. Effects of everolimus on disease progression in bone and bone markers in patients with bone metastases [abstract 512]. J Clin Oncol 2012;30:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=100783; cited December 20, 2012]
48. Beck JT, Rugo HS, Burris HA, et al. bolero-2: health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane [abstract 539]. J Clin Oncol 2012;30:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101451; cited November 8, 2012]
49. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012;134:459-78.
50. Carlson RW, Moench S, Hurria A, et al. nccn Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw 2008;6(suppl 4):S1-25.
51. Pritchard KI, Burris HA, Rugo HS, et al. Safety of everolimus for women over 65 years of age with advanced breast cancer (bc): 12.5-mo follow-up of bolero-2 [abstract 551]. J Clin Oncol 2012;30:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=101036; cited November 15, 2012]
52. Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol 2012;30:587-92.
53. Lindstrom LS, Karlsson E, Wilking UM, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30:2601-8.